Drug interactions
Aprepitant + Vincristine liposomal
Severity: Moderate
Aprepitant and Vincristine liposomal: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Vincristine is a CYP3A4 substrate, and CYP3A4 inhibitors can increase its neurotoxicity. Aprepitant is a moderate inhibitor, so exposure may rise, though liposomal formulation alters its disposition.
What this interaction means in plain words
Aprepitant and Vincristine liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Inhibition of CYP3A4 by aprepitant may reduce vincristine metabolism.
What to do
Monitor for peripheral neuropathy, constipation and ileus, and reduce the vincristine dose if neurotoxicity develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Vincristine liposomal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Aprepitant
- Aprepitant + Lomitapide Contraindicated
- Aprepitant + Pimozide Contraindicated
- Aprepitant + Avapritinib Major
- Aprepitant + Bosutinib Major
- Aprepitant + Carbamazepine Major
- Aprepitant + Cobicistat Major
Frequently asked questions
Can I take Aprepitant with Vincristine liposomal?
MediHelp rates the interaction as moderate. Aprepitant and Vincristine liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Vincristine is a CYP3A4 substrate, and CYP3A4 inhibitors can increase its neurotoxicity. Aprepitant is a moderate inhibitor, so exposure may rise, though liposomal formulation alters its disposition.
How serious is the interaction between Aprepitant and Vincristine liposomal?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for peripheral neuropathy, constipation and ileus, and reduce the vincristine dose if neurotoxicity develops.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
